| 000 | 01630 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250517160141.0 | ||
| 264 | 0 | _c20180719 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1434-9949 | ||
| 024 | 7 |
_a10.1007/s10067-017-3686-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchmitz, E M H | |
| 245 | 0 | 0 |
_aTherapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. _h[electronic resource] |
| 260 |
_bClinical rheumatology _cSep 2017 |
||
| 300 |
_a2129-2134 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBiosimilar Pharmaceuticals _xadministration & dosage |
| 650 | 0 | 4 |
_aC-Reactive Protein _xanalysis |
| 650 | 0 | 4 | _aDrug Monitoring |
| 650 | 0 | 4 | _aDrug Substitution |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInfliximab _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRheumatic Diseases _xdrug therapy |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBenoy-De Keuster, S | |
| 700 | 1 | _aMeier, A J L | |
| 700 | 1 | _aScharnhorst, V | |
| 700 | 1 | _aTraksel, R A M | |
| 700 | 1 | _aBroeren, M A C | |
| 700 | 1 | _aDerijks, L J J | |
| 773 | 0 |
_tClinical rheumatology _gvol. 36 _gno. 9 _gp. 2129-2134 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10067-017-3686-6 _zAvailable from publisher's website |
| 999 |
_c27257502 _d27257502 |
||